News - Pricing

Filter

Current filters:

Pricing

Popular Filters

590 to 614 of 675 results

Brain disorder bill hits 800 billion euros as Europe faces “ticking bomb,” warns EBC study

05-10-2011

The annual cost of brain disorders in Europe has soared to 798 billion euros ($1,070 billion) in what…

EuropeHealthcareNeurologicalPharmaceuticalPricing

AstraZeneca’s Brilique first to be assessed under Germany’s AMNOG, getting positive view

05-10-2011

The German reimbursement body, the Federal Joint Committee (G-BA), has published the Institute for Quality…

AstraZenecaBrilintaBriliqueCardio-vascularEuropePharmaceuticalPricingRegulation

Australian government U-turn on PBS listing of drugs

03-10-2011

More than 160,000 Australians per year will benefit from the Australian Government’s decision to…

Asia-PacificBoehringer IngelheimPharmaceuticalPradaxaPricingRegulation

Portuguese hospitals block access to new medicines as retail drug sector expected to meet savings goal

30-09-2011

Access to expensive medicines is becoming increasingly difficult in Portuguese public hospitals, while…

EuropeHealthcarePfizerPharmaceuticalPricingRare diseasesRegulationVyndaqel

Cost benefit analysis of cervical cancer vaccines sees Gardasil beat Cervarix

29-09-2011

An analysis of cervical-cancer vaccine has shown that Merck & Co’s (NYSE: MRK) Gardasil (human papillomavirus…

CervarixEuropeGardasilGlaxoSmithKlineMerck & CoPharmaceuticalPricingVaccines

Canada’s national health spending crunch the result of public insurance programs, not drug costs

28-09-2011

Claims that prescription drug costs are at the root of Canada’s health spending crisis are unfounded…

HealthcareNorth AmericaPharmaceuticalPricing

German pharma counts cost of drug pricing reforms

27-09-2011

Recent government drug pricing reforms have cost the German pharmaceutical industry billions of euros,…

EuropeFinancialPharmaceuticalPricingResearch

German drug pricing reforms lower health system’s costs, says AVR report

23-09-2011

The multi-year uptrend in drug expenditure by Germany’s health insurers could be ending, according…

EuropeGenericsHealthcarePharmaceuticalPricing

Use of generic Rx drugs saved US consumers and the health care system $931 billion over past 10 years, study finds

23-09-2011

An independently conducted analysis showing that the use of generic prescription drugs in the USA has…

GenericsMarkets & MarketingNorth AmericaPricing

Experts stress the need to improve access to health care in India

19-09-2011

Providing adequate access to medicines and health care is one of the most challenging issues being faced…

Asia-PacificGenericsHealthcarePharmaceuticalPricing

Impax confirms patent challenge to GlaxoSmithKline’s Jalyn; Albemarle hikes API prices

14-09-2011

US generic drugmaker Impax Laboratories (Nasdaq: IPXL) confirms that it has initiated a challenge of…

AlbemarleAvodartGenericsGlaxoSmithKlineImpax LaboratoriesJalynLegalNorth AmericaPatentsPricing

SMC backs Celgene’s Vidaza for rare blood and bone marrow cancers in Scotland

12-09-2011

The Scottish Medicines Consortium (SMC), the equivalent of the UK’s drug watchdog the National Institute…

BiotechnologyCelgeneEuropeOncologyPharmaceuticalPricingRegulationVidaza

Draft guidance from UK's NICE recommends clinical trial for COPD drug Daxas

09-09-2011

New draft guidance from the UK's drug watchdog the National Institute for Health and Clinical Excellence…

DaxasEuropeMerck & CoNycomedPharmaceuticalPricingRegulationRespiratory and Pulmonary

Takeda’s Mepact backed by UK’s NICE for osteosarcoma, after previous negative opinion

07-09-2011

In a U-turn by the UK drug watchdog, in its latest appraisal, the National Institute for Health and Clinical…

EuropeMepactOncologyPharmaceuticalPricingRegulationTakeda Pharmaceuticals

Erbitux and Gilenya added to Australia’s PBS listing

02-09-2011

More than 400,000 Australians will benefit from new subsidized medicines, effective September 1, as Minister…

Asia-PacificErbituxGilenyaMerck KGaANeurologicalNovartisOncologyPharmaceuticalPricingRegulation

PCMA outlines $100 billion in Rx drug savings in USA

01-09-2011

As the USA’s Joint Select Committee on Deficit Reduction examines options to reduce the deficit…

BiotechnologyGenericsHealthcareNorth AmericaPharmaceuticalPricingRegulation

Pfizer’s Pristiq sees private plan formulary access similar to Lilly’s Cymbalta

31-08-2011

In the USA, similar percentages of private health plan lives have formulary access to Pfizer’s (NYSE:…

CymbaltaEli LillyHealthcareNeurologicalNorth AmericaPfizerPharmaceuticalPricingPristiq

Long-term outlook and predictability key to successful medicines policy for Australia, conference told

31-08-2011

A predictable regulatory and reimbursement environment, and a long-term policy outlook are essential…

Asia-PacificPharmaceuticalPricingRegulationResearch

BASF hikes prices for pharmaceutical excipients and active ingredients

30-08-2011

Effective September 1, 2011, Germany-based BASF (BAS: XE), the world’s largest chemical company,…

BASFGenericsPharmaceuticalPricing

Diabetes treatments now 8.4% of UK annual NHS drugs bill, says report

24-08-2011

Diabetes prescriptions now account for 8.4 per of the entire National Health Service net bill for primary…

DiabetesEuropeHealthcareMarkets & MarketingPharmaceuticalPricing

AstraZeneca breast cancer drug Faslodex not good use of NHS resources, says NICE draft guidance

24-08-2011

An independent committee of experts that develops guidance on behalf of the UK drugs watchdog the National…

AstraZenecaEuropeFaslodexOncologyPharmaceuticalPricingRegulation

590 to 614 of 675 results

Back to top